Momordica Charantia Polysaccharides Attenuates MPP+-Induced Injury in PD Mice and Cell Models by Regulating TLR4/MyD88/NF-κB Pathway 2021

[Bolt_Upright]

Momordica Charantia Polysaccharides Attenuates MPP+-Induced Injury in Parkinson’s Disease Mice and Cell Models by Regulating TLR4/MyD88/NF-κB Pathway hindawi.com/journals/ijps/2...

Momordica charantia (colloquially: bitter melon; bitter apple; bitter gourd; bitter squash; balsam-pear ) is a tropical and subtropical vine of the family Cucurbitaceae, widely grown in Asia, Africa, and the Caribbean for its edible fruit.

In summary, this study found that in the PD model, MCPs can regulate the activation state of the TLR4/MyD88/NF-κB pathway, exert protective effects such as anti-inflammatory, antioxidative stress, and antiapoptosis, improve brain function, and provide a new method for the treatment of PD.

Side Effects Of Drinking Bitter Melon Tea That Must Be Considered

youtu.be/Trr5MVnnIsY(Not working as expected?)

[Bolt_Upright]

Neuroprotective effects of Momordica charantia: A review from preclinical studies pharmascope.org/index.php/i...

Medicinal properties of M. charantia have been largely explored in preclinical studies linked to diabetes and cancer. Very few experiments have been attempted to investigate its efficacy in NDs, for ex., AD and neuronal injury. As mentioned earlier, oxidative stress and inflammation are the key pathological hallmarks of NDs. Research in recent years has been focusing on finding traditional herbs or their novel phytochemicals that may target multiple pathological conditions via antioxidant and anti-inflammatory properties. Moreover, they modulate free radical scavenging activity, mitochondrial stress, apoptotic factors, and neurotrophins expression. Preclinical studies revealed that the extract of M. charantia provide neuroprotection via its exemplary antioxidant and anti-inflammatory properties. At molecular level, M. charantia was found to modify PI3K/ATK, JNK3/c-Jun/Fas-L and JNK3/cytochrome C/caspases-3 signaling pathways which are key pathways associated with inflammation. By considering these data we propose that therapeutic efficacy of M. charantia plant must be explored against NDs like ALS, PD, HD and MS using appropriate in vitro and in vivo models. Pathways-targeted phytocompounds identification and isolation from M. charantia shall be initiated and studied in large scale using suitable model systems. Based on the results, clinical trials shall be promoted to treat patients with NDs.

[Bolt_Upright]

Promotion of Momordica Charantia polysaccharides on neural stem cell proliferation by increasing SIRT1 activity after cerebral ischemia/reperfusion in rats sciencedirect.com/science/a...

Highlights

• MCP promotes nerve regeneration after stroke.

• MCP promotes nuclear translocation of β-catenin.

• MCP enhances Sirt1 activity.